Overview Dividends

(HOLX) Hologic - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4364401012

Diagnostics, Imaging, Surgery, Skeletal

HOLX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 2.00%
EPS Trend (3Y Correlation): 44.5%

HOLX Revenue

Revenue Growth (3Y CAGR): -0.84%
Revenue Trend (3Y Correlation): 6.9%

Risk via 10d forecast
Volatility	20.5%
Value at Risk 5%th	31.8%
Relative Tail Risk	-5.79%

Reward TTM
Sharpe Ratio	-0.22
Alpha	-14.34

Character TTM
Hurst Exponent	0.338
Beta	0.319
Beta Downside	0.280

Drawdowns 3y
Max DD	39.85%
Mean DD	15.43%
Median DD	14.99%

Description: HOLX Hologic October 30, 2025

Hologic, Inc. (NASDAQ: HOLX) develops, manufactures, and markets diagnostics, medical imaging, and surgical solutions focused on women’s health, operating through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The firm’s portfolio includes Aptima molecular assays (viral load, bacterial vaginosis, SARS-CoV-2), ThinPrep cytology systems, 3-D digital mammography and related breast-cancer tools, as well as hysteroscopic and orthopedic devices such as MyoSure, NovaSure, and the Horizon DXA scanner.

Key performance indicators from the most recent fiscal year (FY 2023) show total revenue of approximately $5.0 billion, with the Diagnostics segment contributing roughly 55 % of sales and delivering a 14 % operating margin-both above the median for the health-care equipment sub-industry. The Breast Health segment grew 7 % YoY, driven by continued adoption of 3-D mammography, while the GYN Surgical line posted a 5 % increase, reflecting expanding minimally invasive procedures in outpatient settings.

Sector-wide, two macro drivers underpin Hologic’s growth outlook: (1) an aging female population that raises demand for bone-density (DXA) and breast-cancer screening services, and (2) sustained reimbursement pressure on diagnostic assays, which creates a pricing-discipline environment but also incentivizes higher-value, multiplex test platforms. A caveat is that Hologic’s reliance on U.S. Medicare/Medicaid reimbursement rates introduces regulatory-policy uncertainty that could affect future margins.

For a deeper quantitative assessment, you may find ValueRay’s analyst platform useful for drilling into HOLX’s financial metrics and peer comparisons.

HOLX Stock Overview

Market Cap in USD	16,492m
Sub-Industry	Health Care Equipment
IPO / Inception	1990-06-21
Return 12m vs S&P 500	-16.6%
Analyst Rating	3.45 of 5

HOLX Dividends

Currently no dividends paid

HOLX Growth Ratios

CAGR 3y	0.31%
CAGR/Max DD Calmar Ratio	0.01
CAGR/Mean DD Pain Ratio	0.02
Current Volume	5298k
Average Volume	3799.2k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (565.8m TTM) > 0 and > 6% of Revenue (6% = 246.0m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA -0.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 65.63% (prev 69.13%; Δ -3.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.07b > Net Income 565.8m (YES >=105%, WARN >=100%)

Net Debt (548.4m) to EBITDA (1.11b) ratio: 0.49 <= 3.0 (WARN <= 3.5)

Current Ratio 3.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (225.7m) change vs 12m ago -4.34% (target <= -2.0% for YES)

Gross Margin 53.01% (prev 55.78%; Δ -2.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.13% (prev 44.02%; Δ 1.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.26 (EBITDA TTM 1.11b / Interest Expense TTM 98.1m) >= 6 (WARN >= 3)

Altman Z'' 5.06

(A) 0.30 = (Total Current Assets 3.67b - Total Current Liabilities 977.2m) / Total Assets 9.01b

(B) 0.36 = Retained Earnings (Balance) 3.22b / Total Assets 9.01b

(D) 1.27 = Book Value of Equity 5.05b / Total Liabilities 3.97b

Total Rating: 5.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.56

1. Piotroski 6.0pt = 1.0

2. FCF Yield 5.59% = 2.79

3. FCF Margin 22.89% = 5.72

4. Debt/Equity 0.50 = 2.38

5. Debt/Ebitda 0.49 = 2.31

6. ROIC - WACC (= 2.90)% = 3.63

7. RoE 11.74% = 0.98

8. Rev. Trend 6.86% = 0.51

9. EPS Trend 44.52% = 2.23

What is the price of HOLX shares?

As of November 16, 2025, the stock is trading at USD 74.15 with a total of 5,298,045 shares traded.
Over the past week, the price has changed by +0.07%, over one month by +12.48%, over three months by +8.95% and over the past year by -4.37%.

Is Hologic a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Hologic (NASDAQ:HOLX) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 71.56 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOLX is around 67.80 USD . This means that HOLX is currently overvalued and has a potential downside of -8.56%.

Is HOLX a buy, sell or hold?

Hologic has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold HOLX.

Strong Buy: 3
Buy: 3
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the HOLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	75.6	1.9%
Analysts Target Price	75.6	1.9%
ValueRay Target Price	74.1	-0.1%

HOLX Fundamental Data Overview November 10, 2025

Market Cap USD = 16.49b (16.49b USD * 1.0 USD.USD)
P/E Trailing = 29.759
P/E Forward = 14.9254
P/S = 4.022
P/B = 3.1192
P/EG = 1.5076
Beta = 0.705
Revenue TTM = 4.10b USD
EBIT TTM = 809.9m USD
EBITDA TTM = 1.11b USD
Long Term Debt = 2.51b USD (from longTermDebt, two quarters ago)
Short Term Debt = 2.90m USD (from shortTermDebt, last quarter)
Debt = 2.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 548.4m USD (from netDebt column, last quarter)
Enterprise Value = 16.80b USD (16.49b + Debt 2.51b - CCE 2.20b)
Interest Coverage Ratio = 8.26 (Ebit TTM 809.9m / Interest Expense TTM 98.1m)
FCF Yield = 5.59% (FCF TTM 938.7m / Enterprise Value 16.80b)
FCF Margin = 22.89% (FCF TTM 938.7m / Revenue TTM 4.10b)
Net Margin = 13.80% (Net Income TTM 565.8m / Revenue TTM 4.10b)
Gross Margin = 53.01% ((Revenue TTM 4.10b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 60.90% (prev 56.32%)
Tobins Q-Ratio = 1.86 (Enterprise Value 16.80b / Total Assets 9.01b)
Interest Expense / Debt = 0.38% (Interest Expense 9.60m / Debt 2.51b)
Taxrate = 17.63% (40.1m / 227.4m)
NOPAT = 667.1m (EBIT 809.9m * (1 - 17.63%))
Current Ratio = 3.75 (Total Current Assets 3.67b / Total Current Liabilities 977.2m)
Debt / Equity = 0.50 (Debt 2.51b / totalStockholderEquity, last quarter 5.05b)
Debt / EBITDA = 0.49 (Net Debt 548.4m / EBITDA 1.11b)
Debt / FCF = 0.58 (Net Debt 548.4m / FCF TTM 938.7m)
Total Stockholder Equity = 4.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.28% (Net Income 565.8m / Total Assets 9.01b)
RoE = 11.74% (Net Income TTM 565.8m / Total Stockholder Equity 4.82b)
RoCE = 11.05% (EBIT 809.9m / Capital Employed (Equity 4.82b + L.T.Debt 2.51b))
RoIC = 9.19% (NOPAT 667.1m / Invested Capital 7.26b)
WACC = 6.28% (E(16.49b)/V(19.00b) * Re(7.19%) + D(2.51b)/V(19.00b) * Rd(0.38%) * (1-Tc(0.18)))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.06%
[DCF Debug] Terminal Value 77.27% ; FCFE base≈973.0m ; Y1≈910.0m ; Y5≈844.4m
Fair Price DCF = 68.00 (DCF Value 15.14b / Shares Outstanding 222.6m; 5y FCF grow -8.26% → 3.0% )
EPS Correlation: 44.52 | EPS CAGR: 2.00% | SUE: 1.57 | # QB: 2
Revenue Correlation: 6.86 | Revenue CAGR: -0.84% | SUE: 1.79 | # QB: 2

Additional Sources for HOLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle